Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease
Weekly 80 mg adalimumab appears to be an effective and well-tolerated intensification strategy in pediatric CD patients with pharmacokinetic loss of response. Further prospective studies are needed to confirm these findings and guide optimal use.
Authors
- Esther Orlanski‐Meyer (ORCID: https://orcid.org/0000-0001-6481-5936)
- Yael Weintraub (ORCID: https://orcid.org/0000-0002-9748-2872)
- R. Shamir
- Raouf Nassar (ORCID: https://orcid.org/0000-0003-3942-8859)
- Eyal Cohen‐Sela (ORCID: https://orcid.org/0009-0008-0083-9443)
- Firas Rinawi
- Manar Matar
- Dror S. Shouval
- Anat Yerushalmy‐Feler
- Ramit Magen‐Rimon
Institutions
- Tel Aviv University (IL)
- Technion – Israel Institute of Technology (IL)
- Emek Medical Center (IL)
- Soroka Medical Center (IL)
- Rambam Health Care Campus (IL)
- Shaare Zedek Medical Center (IL)
- Schneider Children's Medical Center (IL)
Publication Details
- Journal
- Journal of Pediatric Gastroenterology and Nutrition
- Published
- 2026-03-15
- DOI
- https://doi.org/10.1002/jpn3.70397
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00